News >

PD-1 Blockade Potential Comes to Light in Sarcoma Subtypes

Virginia Powers, PhD
Published: Monday, Feb 06, 2017

Anke van Erp, PhD, MSc

Anke van Erp, PhD, MSc

An immunohistochemistry (IHC) analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam1.

Van Erp noted that this was the first time that high levels of PD-1 expression, either alone or in combination with PD-L1, were demonstrated on the tumors of DSRCT patients, who also showed co-expression of CD8+ cells. Co-chair of the session, Stefan Sleijfer of the Erasmus Medical Center in the Netherlands agreed that the high levels of PD-1, PD-L1, and CD8 expression in DSRCT warrants further investigation into whether PD-1 blockade could have clinical benefit in DSRCT patients.


  1. van Erp A, Versleijen-Jonkers Y, Hillebrandt-Roeffen M, et al. Exploring the potential for PD-1 blockade in sarcoma patients. Presented at: 2017 European Cancer Congress; January 27-30, 2017; Amsterdam, the Netherlands.
  2. Palmerini E, Agostinelli C, Picci P, et al. PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma. Presented at: 2016 ESMO Congress; October 7-10, 2016; Copenhagen, Denmark. Abstract 1399PD.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication